More automation, better manufacturing? What it really takes to scale cell and gene therapy

From scalable processing to AI-enabled QC, where can technology make the biggest difference?

Automation is fast becoming the default answer to scaling cell and gene therapy (CGT) manufacturing. But more automation doesn't automatically mean better manufacturing. The real question is where technology delivers a measurable improvement, and where it simply adds cost and complexity.

23 Nov 2026
| Phacilitate
More automation, better manufacturing? What it really takes to scale cell and gene therapy

The scale-up problem

Processes that work at laboratory or clinical scale don't always translate into efficient commercial production. Manufacturers are under pressure to improve consistency, reduce costs and increase throughput, all while managing complex workflows, limited processing capacity and demanding quality requirements.

Automation, digitalisation and AI-enabled analytical tools all offer potential solutions. The challenge is knowing which technologies genuinely improve manufacturing performance, and which risk becoming expensive additions that don't earn their place.

At Advanced Therapies Week 2027, we're exploring what it really takes to build scalable, commercially viable manufacturing processes.

Where does automation make the biggest difference?

In Session 2, The benchtop bottleneck: Solving the scalable processing shortage, industry leaders will examine which processing tools, platforms and strategies offer the flexibility, scalability and cost-effectiveness needed to accelerate clinical translation and support later-stage development.

Damian Marshall, VP of Analytical Development at Resolution Therapeutics, will also explore how to phase automation into autologous cell therapy manufacturing. His focus: balancing the need to move quickly today with the longer-term requirements of scale.

Rethinking quality control

QC is one of the biggest pressure points in CGT manufacturing, and one of the areas where automation and AI could have the greatest impact.

Our cell and gene therapy characterisation and QC sessions will look at how increasingly automated and AI-enabled analytical approaches can shorten manufacturing timeframes, improve product quality and consistency, and support regulatory compliance.

Contributors include:

  • Stephan Krause, Bristol Myers Squibb, on enhanced analytical control strategies for cell therapies
  • Aishwarya Shevade, Regeneron Pharmaceuticals, on accelerating AAV infectivity assay workflows through automation and AI-assisted data analysis
  • Leaders from Iovance, Tigen Pharma, Resolution Therapeutics and KROMATID, discussing the evolving challenges of cell therapy product characterisation and QC

The questions we'll be asking

Across these discussions, we'll be tackling the questions that matter most to manufacturers right now:

  • Which processes are ready for automation, and where is manual intervention still necessary?
  • How can manufacturers overcome the shortage of scalable benchtop processing solutions?
  • Can automated and AI-enabled analytical tools improve speed and consistency without compromising regulatory requirements?
  • How do we ensure today's manufacturing decisions support future commercialisation?

Not more automation: smarter automation

The goal isn't simply to automate more. It's to identify the technologies and strategies that make advanced therapy manufacturing more efficient, reproducible and commercially sustainable.

Join the discussion at Advanced Therapies Week, 18–21 January 2027, in San Diego.

Explore the manufacturing agenda

Topics
  • Software
  • CDMO / CMO Services
  • COGs optimisation
  • Cell-Based Immuno-Oncology (Cell Based-IO)
  • Software & Digital Tools
  • In-line or at-line sensors/analytics
  • Process development and validation
  • Devices & Hardware
  • CRO Services
  • Assay development
  • 'All-in-one' systems
  • Cell Therapy
  • Cell product manufacturing
  • Advanced Therapies Week
  • GMP compliance
View all Insights & Resources
Loading